Becton, dickinson and company:1106636 [16-053303]

Ended Awarded Last action

Contract number
HHSN26100038
Awardee
Awarding agency
Obligated
$22,702

Award facts

Opportunity
Contract value 100% obligated
$22,701.58 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Time and Materials
Place of performance
Bethesda, MD 20892, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00003 -$0
Funding Only Action 2 $50
Other Administrative Action 1 $0
Original award $22,652

About this award

The National Cancer Institute issued a delivery order to Becton, Dickinson And Company on August 3, 2016, with a ceiling value of $22,701.58 for flow cytometric analysis of benign and malignant tumors.

Place of performance is Bethesda, MD 20892. The order is priced on a time and materials basis and is scheduled for ultimate completion on February 27, 2021.

Quick answers

Who was awarded contract HHSN26100038?

HHSN26100038 was awarded to Becton, Dickinson And Company by National Cancer Institute (National Institutes of Health) on August 3, 2016.

How much is contract HHSN26100038 worth?

The government has obligated $22,702 on HHSN26100038.

Is contract HHSN26100038 an order under another contract?

Yes. HHSN26100038 is a delivery order under HHSN261201400013I, an indefinite delivery contract.

Was contract HHSN26100038 competed?

The extent of competition for HHSN26100038 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award